Skip to Main Content

Paper Details

Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology.
JCO Precis Oncol
2
2019
61 genes, Allogeneic Donor Lymphocyte, CD58, CRTAM, GVHD, GVT, ILF2, PATIENTS, RPL23, activated T cells, acute GVHD, gene, graft-versus-host disease, human, patient, patients, plasma, post-hematopoietic cell transplantation relapse, tumor, tumor antigen-activated T cells
Author NameAffiliation
Xiaowen LiuIndiana University School of Informatics and Computing
Xiaowen LiuIndiana University School of Medicine
Xiaowen LiuIndiana University School of Informatics and Computing
Xiaowen LiuIndiana University School of Medicine
Zongliang YueUniversity of Alabama at Birmingham School of Medicine
Zongliang YueUniversity of Alabama at Birmingham School of Medicine
Yimou CaoIndiana University School of Informatics and Computing
Yimou CaoIndiana University School of Informatics and Computing
Lauren A TaylorIndiana University School of Medicine
Lauren A TaylorIndiana University School of Medicine
Qing ZhangFred Hutchinson Cancer Research Center
Qing ZhangFred Hutchinson Cancer Research Center
Sung Won ChoiUniversity of Michigan ann arbor
Sung Won ChoiUniversity of Michigan ann arbor
Samir M HanashMD Anderson Cancer Center
Samir M HanashMD Anderson Cancer Center
Sawa Itoand Blood Institute
Sawa Itoand Blood Institute
Jake Y. Chen (CM4AI)University of Alabama at Birmingham School of Medicine
Jake Y ChenUniversity of Alabama at Birmingham School of Medicine
Huanmei WuIndiana University School of Informatics and Computing
Huanmei WuIndiana University School of Informatics and Computing
Sophie PaczesnyIndiana University School of Medicine
Sophie PaczesnyIndiana University School of Medicine
  • 1 - 24

Datasets

Release 1.2